Market Overview

JMP Securities Initiates Pernix Therapeutics At Market Outperform


Analysts at JMP Securities initiated coverage on shares of Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) with a Market Outperform rating.

The target price for Pernix Therapeutics is set to $13.

Pernix Therapeutics shares have gained 272.62% over the past 52 weeks, while the S&P 500 index has surged 13.10% in the same period.

Pernix Therapeutics' shares rose 2.85% to close at $9.39 yesterday.

Latest Ratings for PTX

Aug 2016Brean CapitalDowngradesBuyHold
Mar 2016OppenheimerDowngradesOutperformPerform
Mar 2016Brean CapitalMaintainsBuy

View More Analyst Ratings for PTX
View the Latest Analyst Ratings

Posted-In: JMP SecuritiesInitiation Analyst Ratings


Related Articles (PTX)

View Comments and Join the Discussion!

Latest Ratings

PEPMorgan StanleyReiterates137.0
AZRXH.C. WainwrightMaintains7.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Hero: The Reason Behind GoPro's Bounce Back?

UPDATE: Deutsche Bank Initiates Coverage On Cnova